These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cheuk DK; Chiang AK; Chan GC; Ha SY Cochrane Database Syst Rev; 2014 Aug; (8):CD006945. PubMed ID: 25121561 [TBL] [Abstract][Full Text] [Related]
8. Urate oxidase for the prevention and treatment of tumour lysis syndrome in children with cancer. Cheuk DK; Chiang AK; Chan GC; Ha SY Cochrane Database Syst Rev; 2017 Mar; 3(3):CD006945. PubMed ID: 28272834 [TBL] [Abstract][Full Text] [Related]
9. Tumor lysis syndrome: a systematic review of case series and case reports. Firwana BM; Hasan R; Hasan N; Alahdab F; Alnahhas I; Hasan S; Varon J Postgrad Med; 2012 Mar; 124(2):92-101. PubMed ID: 22437219 [TBL] [Abstract][Full Text] [Related]
10. Elitek-rasburicase: an effective means to prevent and treat hyperuricemia associated with tumor lysis syndrome, a Meeting Report, Dallas, Texas, January 2002. Navolanic PM; Pui CH; Larson RA; Bishop MR; Pearce TE; Cairo MS; Goldman SC; Jeha SC; Shanholtz CB; Leonard JP; McCubrey JA Leukemia; 2003 Mar; 17(3):499-514. PubMed ID: 12646938 [TBL] [Abstract][Full Text] [Related]
11. Rasburicase in cancer-related hyperuricemia. Rodriguez M; Campara M; Haaf C Drugs Today (Barc); 2011 Aug; 47(8):591-603. PubMed ID: 21850282 [TBL] [Abstract][Full Text] [Related]
12. Tumor lysis syndrome: new challenges and recent advances. Wilson FP; Berns JS Adv Chronic Kidney Dis; 2014 Jan; 21(1):18-26. PubMed ID: 24359983 [TBL] [Abstract][Full Text] [Related]
13. Comparative effectiveness of rasburicase versus allopurinol for cancer patients with renal dysfunction and hyperuricemia. Martens KL; Khalighi PR; Li S; White AA; Silgard E; Frieze D; Estey E; Garcia DA; Hingorani S; Li A Leuk Res; 2020 Feb; 89():106298. PubMed ID: 31945598 [TBL] [Abstract][Full Text] [Related]
14. Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study. Cortes J; Moore JO; Maziarz RT; Wetzler M; Craig M; Matous J; Luger S; Dey BR; Schiller GJ; Pham D; Abboud CN; Krishnamurthy M; Brown A; Laadem A; Seiter K J Clin Oncol; 2010 Sep; 28(27):4207-13. PubMed ID: 20713865 [TBL] [Abstract][Full Text] [Related]
15. Efficacy and cost of single-dose rasburicase in prevention and treatment of adult tumour lysis syndrome: a meta-analysis. Feng X; Dong K; Pham D; Pence S; Inciardi J; Bhutada NS J Clin Pharm Ther; 2013 Aug; 38(4):301-8. PubMed ID: 23550846 [TBL] [Abstract][Full Text] [Related]
16. Tumour lysis syndrome: new therapeutic strategies and classification. Cairo MS; Bishop M Br J Haematol; 2004 Oct; 127(1):3-11. PubMed ID: 15384972 [TBL] [Abstract][Full Text] [Related]